Medicalgorithmics S.A.: peers
Medicalgorithmics S.A. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Medicalgorithmics S.A., Genomtec S.A., Nano-X Imaging Ltd., Senzime AB (publ), Pulsenmore Ltd.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Medicalgorithmics S.A.base MDG.WA · 🇵🇱 PL Percentile in Healthcare Percentile in Poland | Genomtec S.A. GMT.WA · 🇵🇱 PL Percentile in Healthcare Percentile in Poland | Hyperfine, Inc. HYPR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Nano-X Imaging Ltd. NNOX · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Outset Medical, Inc. OM · 🇺🇸 US Percentile in Healthcare Percentile in USA | Pulmonx Corporation LUNG · 🇺🇸 US Percentile in Healthcare Percentile in USA | Senzime AB (publ) SEZI.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Pulsenmore Ltd. PULS.TA · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $75 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8 | $31 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8 | $78 MOct 23, 2026 · Market data5th of 8 | $70 MAug 1, 2026 · Market data7th of 8 | $82 MOct 28, 2026 · Market data4th of 8 | $86 MOct 28, 2026 · Market data3rd of 8 | $87 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8 | $96 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one1st of 8 | $80 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | $14 MFY2025 · SEC3rd of 6 | $13 MFY2025 · SEC4th of 6 | $119 MFY2025 · SEC1st of 6 | $91 MFY2025 · SEC2nd of 6 | $11 MFY2025 · ESEF6th of 6 | $12 MFY2025 · SEC5th of 6 | $13 M6 ranked |
| Net income (Higher is better) | —— | —— | $-36 MFY2025 · SEC3rd of 6 | $-75 MFY2025 · SEC5th of 6 | $-82 MFY2025 · SEC6th of 6 | $-54 MFY2025 · SEC4th of 6 | $-14 MFY2025 · ESEF2nd of 6 | $-5 MFY2025 · SEC1st of 6 | $-45 M6 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | 102February 15, 2026 · Profile3rd of 3 | —— | 518As on 2022 · Profile1st of 3 | 202As on 2020 · Profile2nd of 3 | —— | —— | 2023 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | —— | —— | —— | 0.0%30 days to Oct 28, 2026 · Market dataonly one with it | —— | —— | 0.0%— |
| Revenue growth (Higher is better) | ———— | ———— | +5.2%FY2025 · SEC5th of 638th46th | +15.4%FY2025 · SEC3rd of 660th61st | +5.1%FY2025 · SEC6th of 638th46th | +8.0%FY2025 · SEC4th of 644th55th | +91.2%FY2025 · ESEF2nd of 690th98th | +344.4%FY2025 · SEC1st of 698th96th | +11.7%6 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | +25.8%FY2025 · SEC1st of 478th89th | +14.9%FY2025 · SEC3rd of 464th62nd | +1.2%FY2025 · SEC4th of 430th37th | +19.0%FY2025 · SEC2nd of 471st84th | ———— | ———— | +17.0%4 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -54.2%FY2025 · SEConly one with it8th22nd | -54.2%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | 49.8%FY2025 · SEC3rd of 636th63rd | -98.2%FY2025 · SEC6th of 61st2nd | 39.1%FY2025 · SEC4th of 624th50th | 74.2%FY2025 · SEC2nd of 672nd86th | 33.3%FY2025 · ESEF5th of 619th41st | 84.1%FY2025 · SEC1st of 685th93rd | 44.5%6 ranked |
| Operating margin (Higher is better) | ———— | ———— | -273.4%FY2025 · SEC4th of 513th4th | -600.8%FY2025 · SEC5th of 54th5th | -55.8%FY2025 · SEC1st of 530th14th | -59.3%FY2025 · SEC2nd of 530th14th | -117.8%FY2025 · ESEF3rd of 521st7th | ———— | -117.8%5 ranked |
| Net margin (Higher is better) | ———— | ———— | -262.3%FY2025 · SEC5th of 612th5th | -576.2%FY2025 · SEC6th of 64th4th | -68.3%FY2025 · SEC3rd of 627th12th | -59.7%FY2025 · SEC2nd of 629th13th | -132.1%FY2025 · ESEF4th of 620th5th | -39.6%FY2025 · SEC1st of 634th28th | -100.2%6 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | -214.8%FY2025 · SEC5th of 614th4th | -345.6%FY2025 · SEC6th of 610th14th | -39.5%FY2025 · SEC2nd of 630th13th | -36.3%FY2025 · SEC1st of 630th14th | -107.5%FY2025 · ESEF4th of 620th3rd | -82.5%FY2025 · SEC3rd of 623rd25th | -95.0%6 ranked |
| Return on equity (Higher is better) | ———— | ———— | -79.0%FY2025 · SEC5th of 631st13th | -45.6%FY2025 · SEC3rd of 646th37th | -106.2%FY2025 · SEC6th of 623rd10th | -77.2%FY2025 · SEC4th of 631st13th | -43.4%FY2025 · ESEF2nd of 647th9th | -17.4%FY2025 · SEC1st of 661st43rd | -61.4%6 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | 4.1×price Oct 23, 2026 · Market data1st of 352nd71st | 5.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.7×price Oct 28, 2026 · Market data3rd of 312th21st | 1.0×price Oct 28, 2026 · Market data2nd of 316th28th | ———— | ———— | 1.0×3 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | 1.9×price Oct 23, 2026 · Market data1st of 336th45th | 0.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.7×price Oct 28, 2026 · Market data3rd of 311th10th | 1.6×price Oct 28, 2026 · Market data2nd of 332nd39th | ———— | ———— | 1.6×3 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | -37.6%price Oct 23, 2026 · Market data1st of 323rd10th | -64.7%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -57.5%price Oct 28, 2026 · Market data3rd of 316th6th | -38.1%price Oct 28, 2026 · Market data2nd of 322nd9th | ———— | ———— | -38.1%3 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | 0.0×FY2025 · SEC1st of 35th3rd | ———— | 0.8×FY2025 · SEC3rd of 368th59th | 0.7×FY2025 · SEC2nd of 364th54th | ———— | ———— | 0.7×3 ranked |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | -4.8×FY2025 · SEConly one with it56th31st | ———— | ———— | ———— | -4.8×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | 6 of 9FY2025 · SEC1st of 2 | 3 of 9FY2025 · SEC2nd of 2 | —— | —— | 4.5 of 92 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | 9 of 22FY2025 · Scorecard2nd of 6 | 5 of 14FY2025 · Scorecard4th of 6 | 8 of 22FY2025 · Scorecard3rd of 6 | 10 of 22FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard6th of 6 | 2 of 6FY2025 · Scorecard5th of 6 | 36% passed6 ranked |
| Valuation checks (Higher is better) | —— | —— | 1 of 5FY2025 · Scorecard3rd of 3 | —— | 2 of 5FY2025 · Scorecard1st of 3 | 2 of 5FY2025 · Scorecard1st of 3 | —— | —— | 40% passed3 ranked |
| Growth checks (Higher is better) | —— | —— | 4 of 6FY2025 · Scorecard1st of 6 | 3 of 5FY2025 · Scorecard3rd of 6 | 3 of 6FY2025 · Scorecard4th of 6 | 4 of 6FY2025 · Scorecard1st of 6 | 1 of 2FY2025 · Scorecard4th of 6 | 1 of 2FY2025 · Scorecard4th of 6 | 55% passed6 ranked |
| Profitability checks (Higher is better) | —— | —— | 1 of 5FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard5th of 6 | 0 of 2FY2025 · Scorecard5th of 6 | 20% passed6 ranked |
| Financial health checks (Higher is better) | —— | —— | 3 of 5FY2025 · Scorecard1st of 5 | 1 of 3FY2025 · Scorecard5th of 5 | 2 of 5FY2025 · Scorecard4th of 5 | 3 of 5FY2025 · Scorecard1st of 5 | —— | 1 of 2FY2025 · Scorecard3rd of 5 | 50% passed5 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | 0 of 1FY2025 · Scorecard1st of 4 | 0 of 1FY2025 · Scorecard1st of 4 | 0 of 1FY2025 · Scorecard1st of 4 | 0 of 1FY2025 · Scorecard1st of 4 | —— | —— | 0% passed4 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | 19.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 7.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | 64.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 61.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | —— | —— | 40.4%4 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | 872026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 742026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | 772026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 1012026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | —— | —— | 824 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | -12.1 pp2026-Q2 against 2026-Q1 · 13F2nd of 3 | -4.3 pp2026-Q2 against 2026-Q1 · 13F1st of 3 | -14.1 pp2026-Q2 against 2026-Q1 · 13F3rd of 3 | —— | —— | -12.1 pp3 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Medicalgorithmics S.A.: How market caps are worked out; Genomtec S.A.: How market caps are worked out; Hyperfine, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nano-X Imaging Ltd.: How market caps are worked out; Outset Medical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Pulmonx Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Senzime AB (publ): How market caps are worked out; Pulsenmore Ltd.: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Medicalgorithmics S.A. | — | — | — |
| Genomtec S.A. | — | — | — |
| Hyperfine, Inc. | -273.4%FY2025 | 13th percentile in Healthcaremedian -7.7%, 674 companies | 4th percentile in USAmedian 3.5%, 2,594 companies |
| Nano-X Imaging Ltd. | -600.8%FY2025 | 4th percentile in Healthcaremedian -7.7%, 674 companies | 5th percentile in Israelmedian -0.2%, 67 companies |
| Outset Medical, Inc. | -55.8%FY2025 | 30th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in USAmedian 3.5%, 2,594 companies |
| Pulmonx Corporation | -59.3%FY2025 | 30th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in USAmedian 3.5%, 2,594 companies |
| Senzime AB (publ) | -117.8%FY2025 | 21st percentile in Healthcaremedian -7.7%, 674 companies | 7th percentile in Swedenmedian 8.0%, 128 companies |
| Pulsenmore Ltd. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Medicalgorithmics S.A. | Genomtec S.A. | Hyperfine, Inc. | Nano-X Imaging Ltd. | Outset Medical, Inc. | Pulmonx Corporation | Senzime AB (publ) | Pulsenmore Ltd. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | $14 MSEC3rd | $13 MSEC4th | $119 MSEC1st | $91 MSEC2nd | $11 MESEF6th | $12 MSEC5th |
| 2024 | — | — | $13 MSEC3rd | $11 MSEC4th | $114 MSEC1st | $84 MSEC2nd | $6 MESEF5th | $3 MSEC6th |
| 2023 | — | — | $11 MSEC3rd | $10 MSEC4th | $130 MSEC1st | $69 MSEC2nd | — | $2 MSEC5th |
| 2022 | — | — | $7 MSEC4th | $9 MSEC3rd | $115 MSEC1st | $54 MSEC2nd | — | — |
| 2021 | — | — | $2 MSEC3rd | — | $103 MSEC1st | $48 MSEC2nd | — | — |
| 2020 | — | — | $0 MSEC3rd | — | $50 MSEC1st | $33 MSEC2nd | — | — |
| 2019 | — | — | — | — | $15 MSEC2nd | $33 MSEC1st | — | — |
| 2018 | — | — | — | — | $2 MSEC2nd | $20 MSEC1st | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Medicalgorithmics S.A.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Genomtec S.A.GMT.WA · 🇵🇱 PolandSame industry: Medical Devices · Similar size: $31 M market cap against $75 M · Same country: PolandMarket cap $31 M (last known, Jan 5, 2024)89 of 100 (industry or sector 50 + size 24 + country 15)In the group
- Hyperfine, Inc.HYPR · 🇺🇸 USASame industry: Medical Devices · Similar size: $78 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $78 M (Oct 23, 2026) · revenue $14 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Nano-X Imaging Ltd.NNOX · 🇮🇱 IsraelSame industry: Medical Devices · Similar size: $70 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $70 M (Aug 1, 2026) · revenue $13 M (year to December 2025)84 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Outset Medical, Inc.OM · 🇺🇸 USASame industry: Medical Devices · Similar size: $82 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $82 M (Oct 28, 2026) · revenue $119 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Pulmonx CorporationLUNG · 🇺🇸 USASame industry: Medical Devices · Similar size: $86 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $86 M (Oct 28, 2026) · revenue $91 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Senzime AB (publ)SEZI.ST · 🇸🇪 SwedenSame industry: Medical Devices · Similar size: $87 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $87 M (last known, Jan 5, 2024) · revenue $11 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Pulsenmore Ltd.PULS.TA · 🇮🇱 IsraelSame industry: Medical Devices · Similar size: $96 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $96 M (last known, Jan 5, 2024) · revenue $12 M (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)In the group
- Neuraxis, Inc.NRXS · 🇺🇸 USASame industry: Medical Devices · Similar size: $95 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $95 M (Oct 13, 2026) · revenue $4 M (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Apyx Medical CorporationAPYX · 🇺🇸 USASame industry: Medical Devices · Similar size: $99 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $99 M (Oct 9, 2026) · revenue $53 M (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Sensus Healthcare, Inc.SRTS · 🇺🇸 USASame industry: Medical Devices · Similar size: $49 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $49 M (Oct 1, 2026) · revenue $27 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)+ Add
- Precision Optics Corporation, Inc.POCI · 🇺🇸 USASame industry: Medical Devices · Similar size: $48 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $48 M (Aug 1, 2026) · revenue $32 M (year to June 2026)82 of 100 (industry or sector 50 + size 27 + figures on file 5)+ Add
- CVRx, Inc.CVRX · 🇺🇸 USASame industry: Medical Devices · Similar size: $48 M market cap against $75 M · Ratios of the last two fiscal years on fileMarket cap $48 M (Oct 9, 2026) · revenue $57 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.